Sarepta said it is stopping enrollment in a confirmatory Phase 3 trial of Elevidys for Duchenne muscular dystrophy in older boys, a move that tightens execution around the company’s next evidence plan. Separately, Satellos reported a change to a Duchenne study primary endpoint for forazapadin, signaling a shift in how the program will measure benefit.